Literature DB >> 8313948

Public funding for contraceptive, sterilization and abortion services, fiscal year 1992.

D Daley1, R B Gold.   

Abstract

In 1992, the federal and state governments spent $645 million to provide contraceptive services. According to the results of a survey of health, social service and Medicaid agencies conducted by The Alan Guttmacher Institute, Medicaid accounted for 50% of all public spending on family planning services. State governments, which spent a total of $155 million of their own revenues for contraceptives services, accounted for 24% of public funding, Title X for 17%, and the social services and maternal and child health block-grant programs for nearly 10%. Medicaid expenditures for contraceptive services increased dramatically between 1990 and 1992, and were responsible for a 28% rise in total expenditures for contraceptive services during that period. However, when inflation is taken into account, total public expenditures for contraceptive services have decreased by 27% since 1980, and Medicaid has replaced Title X as the primary source of funding for such services. The federal and state governments together spent $138 million to subsidize sterilization services in 1992, an increase of 46% from 1990. The federal and state governments also spent $80 million to provide 202,622 abortions to poor women; less than 1% was contributed by the federal government. These estimates of expenditures are approximations that, because of methodologic problems and changes over time, may overstate public expenditures for contraceptive services.

Entities:  

Keywords:  Genetics and Reproduction

Mesh:

Year:  1993        PMID: 8313948

Source DB:  PubMed          Journal:  Fam Plann Perspect        ISSN: 0014-7354


  2 in total

1.  A contract on American's children.

Authors:  C A Miller
Journal:  Am J Public Health       Date:  1996-04       Impact factor: 9.308

2.  The economic value of contraception: a comparison of 15 methods.

Authors:  J Trussell; J A Leveque; J D Koenig; R London; S Borden; J Henneberry; K D LaGuardia; F Stewart; T G Wilson; S Wysocki
Journal:  Am J Public Health       Date:  1995-04       Impact factor: 9.308

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.